ReviewFrontiers in digital health2026
International perspectives on AI-driven pharmaceutical IP challenges.
Review in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial Intelligence (AI) is transforming the pharmaceutical sector by optimizing care delivery and accelerating drug design. While AI introduces significant benefits, it presents complex challenges regarding intellectual property (IP) frameworks. This review examines AI-driven innovations in personalized medicine and drug design, with a specific focus on inventorship issues that directly affect pharmaceutical patent protection. We analyze recent United States (US) legal developments concerning AI inventorship, including the US Supreme Court's March 2026 denial of certiorari in Thaler v. Perlmutter, which definitively resolved the question of AI inventorship under US law, provide comparative analyses of approaches in Germany and China, and identify specific lessons, rather than wholesale reforms, that may help stakeholders navigate the evolving intersection of AI and pharmaceutical IP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.